Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients

Racial disparities in incidence and outcome in multiple myeloma: a population-based study

(2010) A. J. Waxman et al.   BLOOD

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tanespimycin: the opportunities and challenges of targeting heat shock protein 90

(2009) Charles Erlichman   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010

(2009) H. Brenner et al.   HAEMATOLOGICA

Pomalidomide (CC4047) Plus Low-Dose Dexamethasone As Therapy for Relapsed Multiple Myeloma

(2009) Martha Q. Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation

(2009) C. Fionda et al.   JOURNAL OF IMMUNOLOGY

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

First thalidomide clinical trial in multiple myeloma: a decade

(2008) F. van Rhee et al.   BLOOD

Perifosine Synergistically Enhances TRAIL-Induced Myeloma Cell Apoptosis via Up-Regulation of Death Receptors

(2008) E. David et al.   CLINICAL CANCER RESEARCH

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE